- Home
- OCSL vs ELVN Comparison
OCSL vs ELVN Comparison
Compare OCSL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCSL | ELVN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OCSL | ELVN |
|---|---|---|
| Price | $12.90 | $26.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $14.25 | ★ $41.00 |
| AVG Volume (30 Days) | 829.7K | ★ 1.4M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | ★ 12.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $316,801,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | $32.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $13.30 |
| 52 Week High | $16.29 | $29.98 |
Technical Indicators
Market Signals| Indicator | OCSL | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 71.86 |
| Support Level | $12.55 | $24.29 |
| Resistance Level | $13.06 | $27.42 |
| Average True Range (ATR) | 0.24 | 2.30 |
| MACD | 0.05 | 1.20 |
| Stochastic Oscillator | 75.82 | 80.06 |
Price Performance
Historical ComparisonAbout OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.